Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Human immunodeficiency-causing mutation defines CD16 in spontaneous NK cell cytotoxicity
Jennifer T. Grier, … , Kerry S. Campbell, Jordan S. Orange
Jennifer T. Grier, … , Kerry S. Campbell, Jordan S. Orange
Published September 24, 2012
Citation Information: J Clin Invest. 2012;122(10):3769-3780. https://doi.org/10.1172/JCI64837.
View: Text | PDF
Research Article Immunology Article has an altmetric score of 16

Human immunodeficiency-causing mutation defines CD16 in spontaneous NK cell cytotoxicity

  • Text
  • PDF
Abstract

The Fc receptor on NK cells, FcγRIIIA (CD16), has been extensively studied for its role in mediating antibody-dependent cellular cytotoxicity (ADCC). A homozygous missense mutation in CD16 (encoding a L66H substitution) is associated with severe herpesvirus infections in rare patients. Here, we identified a new patient with this CD16 mutation and compared the patient’s NK cells to those of the originally reported patient. Patients with the L66H mutation had intact ADCC, but deficient spontaneous NK cell cytotoxicity and decreased surface expression of CD2, a coactivation receptor. Mechanistic studies in a human NK cell line, NK-92, demonstrated that CD16 expression correlated with CD2 surface levels and enabled killing of a melanoma cell line typically resistant to CD16-deficient NK-92 cells. An association between CD16 and CD2 was identified biochemically and at the immunological synapse, which elicited CD16 signaling after CD2 engagement. Stable expression of CD16 L66H in NK-92 cells recapitulated the patient phenotype, abrogating association of CD16 with CD2 as well as CD16 signaling after CD2 ligation. Thus, CD16 serves a role in NK cell–mediated spontaneous cytotoxicity through a specific association with CD2 and represents a potential mechanism underlying a human congenital immunodeficiency.

Authors

Jennifer T. Grier, Lisa R. Forbes, Linda Monaco-Shawver, Jennifer Oshinsky, T. Prescott Atkinson, Curtis Moody, Rahul Pandey, Kerry S. Campbell, Jordan S. Orange

×

Figure 1

Point mutation in CD16 results in CD16 B73.1 epitope loss and decreased natural killing without affecting ADCC.

Options: View larger image (or click on image) Download as PowerPoint
Point mutation in CD16 results in CD16 B73.1 epitope loss and decreased ...
(A) FACS analysis of CD3–CD56+ NK cells from a control donor and patient 1 for CD16 3G8 and CD16 B73.1 epitopes. (B) Sequence analysis of CD16 within the region corresponding to the B73.1 epitope in a normal donor and patient 1. (C) NK cell lytic units (LU20) against K562 cells for patient 1 and control (n = 3 independent experiments). (D) ADCC assay of patient 1 or control PBMCs against Raji cells in the presence or absence of rituximab (representative of n = 3 independent experiments).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 1 X users
Referenced in 5 patents
Referenced in 1 Wikipedia pages
153 readers on Mendeley
See more details